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Background: Public health risks associated to infection by human coronaviruses remain considerable and
vaccination is a key option for preventing the resurgence of severe acute respiratory syndrome coronavirus
(SARS-CoV). We have previously reported that antibodies elicited by a SARS-CoV vaccine candidate based on
recombinant, full-length SARS-CoV Spike-protein trimers, trigger infection of immune cell lines. These observations
prompted us to investigate the molecular mechanisms and responses to antibody-mediated infection in human
macrophages.
Methods: We have used primary human immune cells to evaluate their susceptibility to infection by SARS-CoV in
the presence of anti-Spike antibodies. Fluorescence microscopy and real-time quantitative reverse transcriptase
polymerase chain reaction (RT-PCR) were utilized to assess occurrence and consequences of infection. To gain
insight into the underlying molecular mechanism, we performed mutational analysis with a series of truncated and
chimeric constructs of fragment crystallizable γ receptors (FcγR), which bind antibody-coated pathogens.
Results: We show here that anti-Spike immune serum increased infection of human monocyte-derived
macrophages by replication-competent SARS-CoV as well as Spike-pseudotyped lentiviral particles (SARS-CoVpp).
Macrophages infected with SARS-CoV, however, did not support productive replication of the virus. Purified
anti-viral IgGs, but not other soluble factor(s) from heat-inactivated mouse immune serum, were sufficient to
enhance infection. Antibody-mediated infection was dependent on signaling-competent members of the human
FcγRII family, which were shown to confer susceptibility to otherwise naïve ST486 cells, as binding of immune
complexes to cell surface FcγRII was necessary but not sufficient to trigger antibody-dependent enhancement
(ADE) of infection. Furthermore, only FcγRII with intact cytoplasmic signaling domains were competent to sustain
ADE of SARS-CoVpp infection, thus providing additional information on the role of downstream signaling by FcγRII.
Conclusions: These results demonstrate that human macrophages can be infected by SARS-CoV as a result of
IgG-mediated ADE and indicate that this infection route requires signaling pathways activated downstream of
binding to FcγRII receptors.
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The continuous threat of respiratory viruses to public
health was exemplified by the global impact of the SARS-
CoV outbreak in 2003 [1], by the occurrence since 2003 of
confirmed human cases of H5N1 avian influenza in many
countries, particularly across Asia [2], and the 2009 H1N1
influenza pandemic [3]. The recent emergence in the
Arab peninsula of a novel coronavirus responsible for
the Middle East respiratory syndrome (MERS-CoV),
[4,5] and the new H7N9 strain of avian influenza that
has jumped into humans [6,7] in China underscore the
need to continue work in this direction.
It is now agreed that SARS-CoV can infect not only
the respiratory tract, but can also affect other organ sys-
tems and several reports have demonstrated infection of
hematopoietic cells [8-10]; however, the mechanism by
which SARS-CoV enters into immune cells, which do not
express the SARS-CoV receptor angiotensin-converting
enzyme 2 (ACE2) [11,12] has remained poorly under-
stood. Both C-type lectin receptors such as liver/lymph
node-specific intercellular adhesion molecule-3-grabbing
integrin (L-SIGN) or dendritic cell specific intercellular
adhesion molecule 3-grabbing non-integrin (DC-SIGN)
[13,14], as well as antibody-mediated infection may
provide SARS-CoV with an opportunity to modify its
tropism.
Because of the lack of effective antiviral strategies
to control coronaviruses infections, vaccination is still
regarded as a major option for preventing resurgence of
SARS and related diseases. We previously showed that a
SARS-CoV vaccine candidate based on recombinant,
full-length SARS-CoV Spike-protein trimers triggered
infection of human B cell lines despite eliciting in vivo a
neutralizing and protective immune response in rodents
[15]. More recently, we demonstrated that anti-Spike
antibody potentiates infection of both monocytic and
lymphoid immune cell lines, not only by SARS-CoVpp
but also by replication-competent SARS-coronavirus [16],
thus providing evidence for a novel and versatile mechan-
ism by which SARS-CoV can enter into target cells that
do not express the conventional ACE2 virus receptor and
are otherwise refractory to the virus. Such infection path-
way may have implications for understanding the tropism
and pathogenesis of the virus and, therefore, we further
investigated the molecular and cellular mechanisms under-
lying ADE of SARS-CoV infection.
By monitoring the susceptibility of human bulk primary
immune cells (i.e. peripheral blood mononuclear cells) we
have established the occurrence of ADE of SARS-CoVpp
infection in different circulating immune cell types, among
which the monocytic lineage (CD68+ cells) was the pri-
mary target. In addition to monocytes, human macro-
phages were also infected by SARS-CoV in presence of
anti-Spike antibodies only. ADE-mediated infection ofmacrophages, however, did not support productive rep-
lication of the virus. Finally, we have provided evidence
that the intracellular signaling motif – but not the IgG
binding motif – of the FcγR is the key molecular deter-
minant for triggering ADE of SARS-CoVpp. Our findings
conclusively demonstrate that anti-spike serum promotes
internalization of SARS-CoV by human macrophages.
Results
Primary human macrophages are susceptible to
SARS-CoV infection through antibody-mediated pathway
Because our previous observations revealed that a human
monocytic cell line THP-1 was susceptible to ADE of
infection [16], we investigated the occurrence of ADE of
infection in primary human macrophages in vitro, firstly
by taking advantage of SARS-CoVpp that can be safely
used to mimic the viral entry process [15,17]. We found
that SARS-CoVpp opsonized with a 1:1000 dilution of
anti-Spike serum readily infected over 80% of primary
human macrophages, as determined by immunofluores-
cence staining of firefly luciferase at 72 hours post infec-
tion (h.p.i.). By contrast, cells exposed to SARS-CoVpp
opsonized with control serum did not show any positive
staining of the luciferase reporter protein (Figure 1). These
experiments extend our previous observations and indi-
cate that anti-Spike antibodies facilitate infection of SARS-
CoVpp into human macrophages. We next tested whether
this altered tropism was also displayed by replication-
competent SARS-CoV. Human macrophages were in-
fected at a multiplicity of infection (MOI) of 1 with the
same dilutions of anti-Spike or control immune serum
and the infection pattern was examined by both im-
munofluorescence staining of SARS-CoV nucleocapsid
protein and real-time quantitative PCR measurement of
viral RNAs. Positive immunofluorescence signals were
detected only at 6 h.p.i. when SARS-CoV was opsonized
with both control and anti-Spike serum (Figure 2). Inter-
estingly, whereas presence of control serum led to only
modest infection by SARS-CoV (~5% of cells), a 4-fold in-
crease in the percentage of positive cells was noted in the
presence of anti-Spike serum for two out of three donors
(Figure 2). Such enhanced infection pattern was paralleled
by the number of viral gene copies measured (Figure 3).
Thus, compared to inoculums containing control serum,
there was a 2 to 3-fold increase in the detection of both
positive and negative strands of viral genes in macro-
phages infected in presence of anti-Spike serum, which
was more pronounced at 1 and 6 h.p.i. There was a rapid
decline in viral RNA from 6 to 24 h.p.i. for both conditions
and no further changes were detected at later time points
(Figure 3). However, it should be noted that the primer
set used for the nucleocapsid gene could also detect the
negative strand of the viral genomic RNA and could not
distinguish it from sub-genomic material. In addition,
Figure 1 Anti-Spike but not control serum triggered infection of human macrophages by SARS-CoVpp. (A) Monocyte-derived macrophages
were incubated for 1 hour with SARS-CoVpp carrying a luciferase reporter gene in the presence of a 1:1000 dilution of either anti-Spike or control
serum and infected cells were detected by fluorescence staining of firefly luciferase (green), as described under Materials and methods. Cell nuclei were
labeled with DAPI (blue). SARS-CoVpp infection of macrophages occurred only in the presence of anti-Spike serum. Images are representatives
of five independent experiments using macrophages from five donors. (B) Infection was quantified by counting the percentage of
immunofluorescence-positive cells in randomly chosen fields using Metamorph software. Results are shown as means ± SEM. Scale bar: 20 μm.
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both viral nucleocapsid and ORF1b genes in culture su-
pernatants to determine the release of SARS-CoV parti-
cles from the infected macrophages. Copy numbers of
both viral RNAs, however, remained unchanged at all
the selected time points during the course of the experi-
ment (less than 200 copies/μl), regardless of whether
macrophages had been infected in the presence of either
control or anti-Spike serum (data not shown).
ADE of SARS-CoVpp infection is dependent on the dose
of IgG fraction of heat-inactivated immune-serum
We have previously demonstrated that mouse anti-
Spike serum could trigger infection of Raji cells [16]. In
the context of ADE, antibodies against viral proteins are
considered as the major players of enhancement [18,19];
see for review [20,21]. To eliminate the possibility of the
participation of other soluble factors during ADE of SARS,
in this section we investigated the capability of anti-Spike
antibodies alone in enhancing infection of immune cells.
We purified IgG by protein G-sepharose chromatography
from mouse anti-Spike and control serum, and used 2-
fold serial dilutions from 10 to 0.125 μg/mL of the purified
portion to form immune complex with SARS-CoVpp
and then infected Raji cells. Our results show that puri-
fied IgG from mouse anti-Spike serum triggered infec-
tion in Raji cells, which was more pronounced with
increasing immunoglobulin concentrations (Figure 4).
The flow-through (FT) from the same serum, whichwas diluted by the appropriate factor to be comparable
to the final IgG concentration used, elicited no detectable
infection at all concentrations (data not shown). Signifi-
cant differences between ADE of infection with purified
mouse anti-Spike IgG and flow-through were observed at
concentrations 10 and 2.5 μg/mL, and marginal differ-
ence was observed at 0.625 μg/mL. As expected, neither
purified IgG (Figure 4) nor flow-through from mouse
control serum triggered significant ADE of infection at
all concentrations.
Molecular determinants of FcγRII underlying ADE of
SARS-CoVpp
Our recent work had revealed the predominant role of
human FcγRII (CD32) in mediating ADE of SARS-CoV
[16]. To gain further insight into the underlying molecular
mechanism we have investigated the involvement of differ-
ent domains of FcγRII in mediating ADE. To this end we
produced a series of truncated constructs that only carried
ectodomain and transmembrane domains of FcγRII,
and chimeric constructs with the ectodomain of one re-
ceptor and transmembrane and endodomain of another
(Figure 5A). We then verified the expression of these
constructs on ST486 cells by flow cytometry using a
specific monoclonal antibody (clone FLI8.26) that binds
to the second Ig-like domain D2γ of FcγRII. Of note,
the Fc binding portion of the FcγRII group is very simi-
lar among FcγRIIA-H131, FcγRIIA-R131, FcγRIIB1 [22]
and also FcγRIIB2, as it harbors identical extracellular
Figure 2 Anti-Spike serum enhanced SARS-CoV infection in human monocyte-derived macrophages. (A) Monocyte-derived macrophages
were infected with SARS-CoV (strain HK39849) at an MOI of 1 in the presence of a 1:1000 dilution of either anti-Spike (black bars) or control (white
bars) serum for 1 hour and then cultured with fresh medium for 6 hours as described under Materials and methods. After fixation, cells were
permeabilized for intracellular staining of SARS-CoV nucleocapsid protein, which was revealed by TRITC-conjugated goat anti-mouse antibody (orange)
while cell nuclei were stained with DAPI (blue). Images shown are representatives of the results obtained with macrophages from three donors at
6 hours post infection. Scale bar: 20 μm. (B) Infectivity of SARS-CoV was determined by calculating the percentage of nucleocapsid-positive cells in five
randomly selected fields using Metamorph software. Presence of anti-Spike serum increased infectivity of SARS-CoV by 3-4-fold in macrophages of two
out of three donors. Note that the ordinate’s scale for Donor 3 is different for ease of visualization. Results are shown as means ± SEM.
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FcγRII constructs exhibited detectable expression of
FcγRII (dark grey) in ST486 cells in comparison to iso-
type control (light grey) (Figure 5B). We then tested the
ability of the various constructs to bind purified anti-
Spike IgG-SARS-CoVpp immune complexes and ob-
served that all ST486 transfectants were able to bind
immune complexes (Figure 5C). Finally we investigated
whether any difference in susceptibility to SARS-CoVpp
ADE of infection was conferred by different FcγRII con-
structs. When immune complexes formed by 5 μg/mL
of purified mouse anti-Spike IgG (the concentration at
which the highest infection level was observed in Raji
cells) and SARS-CoVpp were added to FcγRII-expressing
ST486 cells, all four transfectants expressing wild-
type FcγRII forms (cf. FcγRIIA-H vs. FcγRIIA-R, and
FcγRIIB1 vs. FcγRIIB2, corresponding to constructs 1,
5, 9, 10, respectively) were infected (Figure 5D), with
FcγRIIA-expressing ST486 being more prone to infec-
tion than FcγRIIB (cf, constructs 1 and 5 with 9). All
the endodomain-truncated constructs (FcγRIIA-H.ΔIC,
FcγRIIA-R.ΔIC and FcγRIIB.ΔIC, corresponding to con-
structs 2, 6, 11 respectively) were not susceptible to
ADE of infection, indicating that binding of anti-SpikeIgG-SARS-CoVpp immune complexes was not suffi-
cient to mediate entry and that the signaling-competent
endodomain was required. However, not all chimeric
constructs were able to sustain ADE of infection, sug-
gesting that domain swapping may have partially inter-
fered with signal transduction. Thus only chimeras with
FcγRIIA-H ectodomain and FcγRIIB1 endomain, or with
FcγRIIB ectodomain and FcγRIIA endomain, exhibited a
statistically significant ADE of infection (Figure 5D). This
cannot be explained by differences in surface expression
or binding of opsonized pseudoparticles, as FcγRIIB.EC/
IIA.IC (viz., construct 12) showed robust ADE despite one
of the lowest binding ability of immune-complexes.Discussion
The possibility that immune response to pathogens may
have also deleterious effects on the host homeostasis
has been the focus of several studies. For example, the
hyper-induction of cytokines following avian influenza
infection has been implicated in the severity of the dis-
ease [23] and infection of cells by ADE has been known
to occur for several viral diseases [20,21]. Here we dem-
onstrate that anti-Spike antibody potentiates infection
1 6 24 72
0
3000
6000
9000
1 6 24 72
0
100
200
1 6 24 72
0
2000
4000
6000
1 6 24 72
0
30
60
90
1 6 24 72
0
100
200
1 6 24 72
0
10
20
1 6 24 72
0
1000
2000
1 6 24 72
0
3
6
9
1 6 24 72
0
1000
2000
1 6 24 72
0
10
20
30
1 6 24 72
0
500
1000
1500
1 6 24 72
0
3
6
9
D
on
o
r 
1
D
on
o
r 
2
D
on
o
r 
3
Nucleocapsid ORF1b
Positive strand Negative strand Positive strand Negative strand
Control Anti-Spike
A B
ge
n
e 
c
o
pi
e
s/
10
8  
18
S 
rR
NA
 
co
pi
es
hour(s) post infection (hp.i.)
Figure 3 Nucleocapsid and ORF1b gene expression in SARS-CoV infected human macrophages. Monocyte-derived macrophages from
three independent donors were infected with SARS-CoV as described in the legend to Figure 2 in the presence of anti-Spike (black bars) or control
serum (white bars). Positive and negative RNA strands were determined for SARS-CoV nucleocapsid (A) and ORF1b (B) at the specified time points
(hours) post infection (h.p.i.) using real-time qPCR. Data are shown as the number of viral RNA copies normalized to that of 108 copies of 18S rRNA in
the corresponding sample. Overall, RNA levels were higher in infected cells in presence of anti-Spike compared to control serum. Results are shown as
means ± SEM of four measurements from two separate runs for each donor and gene.
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replication-competent SARS-coronavirus.
Although we unambiguously obtained evidence of on-
going infection (e.g., de novo synthesis of the structural
viral protein N), ADE-infected macrophages did not
support productive replication of SARS-CoV and, after
initiation of viral gene transcription and viral protein
synthesis, the replication process stalled ultimately end-
ing in an abortive viral cycle without detectable release
of progeny virus. Abortive replication of SARS-CoV
into macrophages has already been documented [24]
but, at variance with this previous report in which 90%
of the macrophages were infected by SARS-CoV in the
absence of immune-serum (MOI = 1–2), we observed a
much lower infection rate (about 5-7%). One possibility
is that such discrepancy may be due to difference of
time of sampling (6 hours in our study versus 15 hours
in Cheung’s study) and the protocol used for in vitro
differentiation (viz., macrophages were differentiated in
the presence of fetal calf serum in our study, and au-
tologous plasma was removed two days prior to infec-
tion in ref. [8]), leading to difference in infectivity of the
cells observed in the studies. Alternatively, we should
also consider that the readout of the pseudo-particle ex-
periments was the expression of the luciferase reporter
gene, which is under the control of the HIV backbone.This may lead to higher level of protein expression
when compared to the abortive replication that follows
SARS-CoV infection of macrophages. Thus, the difference
may be, in part due to the inability to detect low amounts
of Spike protein by immunofluorescence and the differ-
ence in sensitivity of the two methods. Of note, the anti-
Spike mediated entry is specific for Spike-pseudotyped
particles, as shown in Figure 1 of [16].
Because clinical observations have reported poor disease
outcomes in early seroconverted SARS patients [25-27], it
would be of interest to test SARS patient sera collected at
different time-points after SARS onset. However, we have
been unable thus far to conduct conclusive assays on a
well characterized serum library; moreover, we have to be
cognizant of the possibility that ADE may only occur
within a narrow window during the course of an infection
and only in a subset of infected patients. The alternative
possibility that internalization by macrophages may in fact
represent an additional mechanism to control viral spread
requires further investigation.
In general, studies aiming at better understanding
antibody-dependent enhancement of viral infections are
focusing on either identifying the (immune) receptor(s)
and/or serum component(s) allowing penetration of the
pathogen into the target cell, also known as extrinsic
ADE, or the outcome response(s) of the target cell
Figure 4 Purified IgGs from heat-inactivated mouse anti-Spike
serum mediate ADE of infection of Raji cells by SARS-CoVpp.
Serial dilutions of purified IgGs (solid bars) and protein G-sepharose
column flow-through (hatched bars) from either heat-inactivated
mouse anti-Spike (dark grey) or control (light grey) serum were
incubated with SARS-CoVpp for 1 hour and opsonized particles were
then used to infect Raji cells as described under Materials and
methods. SARS-CoVpp infection was assessed three days post infection
by expressing luciferase activity as Relative Luminescence Units (RLU),
as described under Materials and methods. IgG concentrations
were used to calculate the dilution factor and adjust the amount of
the corresponding flow-through (FT, hatched bars) from the
purification columns. Results are shown as means ± SEM of 6
measurements from two independent experiments. *P < 0.05 (by
the unpaired Student’s t test).
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[20,21,28]. Our previous results demonstrated that only
FcγRIIA and, to a lesser extent, FcγRIIB1 triggered in-
fection by SARS-CoVpp in presence of anti-Spike serum
[16]. Although it would have been desirable to perform
FcγR blocking experiments also in macrophages, co-
expression of all FcγRs in these cells [29,30] would
cause blocking antibodies to bind not only to the tar-
geted FcγR via their Fab portions, but also to other FcγR
via their Fc portion making both FcγRs unavailable for
interaction with opsonized pseudoparticles and, conse-
quently, would prevent unambiguous interpretation of the
results. We therefore investigated the molecular/signaling
requirement underlying FcγRII-mediated infection by
SARS-CoV and assessed the relative contribution of the
extracellular versus the transmembrane and intracellu-
lar domains of the Fcγ receptor II family members in me-
diating ADE of infection. The extracellular IgG-binding
domains of human FcγRIIA and FcγRIIB are closely re-
lated, with 78% of homology at the amino acid level.
Nonetheless, these 2 receptors have distinct abilities
and affinities for the binding of immunoglobulins [31].
Moreover, FcγRIIA carries an immunoreceptor tyrosine-
based activation motif (ITAM) whereas FcγRIIB carries an
immunoreceptor tyrosine-based inhibitory motif (ITIM),
which confer IgG receptors different effector properties[29,30,32]. Altogether, our results demonstrate that bind-
ing of SARS-CoVpp to cells via the extracellular domain
of FcγRs is not sufficient to trigger ADE of infection as
entry requires an intact intracellular domain. Indeed, in
spite of roughly similar expression level at the cell sur-
face compared to wild type FcγRII, all mutated FcγRII
receptors having truncation of their intracellular domain
(FcγRIIΔIC) became unable to trigger ADE of infection
while retaining significant level of ligand-bind ability. The
results obtained with chimeric constructions where the
whole intracellular domain of FcγRIIA and FcγRIIB were
swapped lend further support to this interpretation. Of
note, the transmembrane and intracellular domains ap-
peared to impart susceptibility to infection of their par-
ental FcγRII. Thus, wild-type FcγRIIA elicited greater
ADE than FcγRIIB and grafting the cytoplasmic portion
of FcγRIIB reduced susceptibility to ADE of the chimeras
with an extracellular FcγRIIA domain to levels comparable
to those observed for the FcγRIIA truncated mutants.
However, the relationship between internalization of
immune complexes and ADE of infection by SARS-CoV
via FcγRIIs appears to be a complex process. Thus,
FcγRIIB2 has been shown to mediate internalization of
immune complexes at a faster rate than FcγRIIA [33],
whereas we found that ADE of infection via FcγRIIA
was more prominent than with FcγRIIB. Recently, in-
volvement of downstream signaling triggered by FcγRs
activation has been evaluated with respect to ADE of
dengue virus infection [34]. Thus, abrogation of FcγRI
and FcγRII signaling competency was associated with
significant impairment of phagocytosis, but only the
signaling-incompetent FcγRI become unable to trigger
ADE of dengue virus. Conversely, no discernible effect on
dengue virus immune complex infectivity was observed
for both wild type and signaling incompetent FcγRIIA.
These findings point to fundamental differences between
FcγRIA and FcγRIIA with respect to their immune-
enhancing capabilities and suggest that different mecha-
nisms of dengue virus immune complex internalization
may operate between these FcγRs [34].
Conclusions
Altogether our results demonstrate that, in presence of
vaccine-elicited antiviral antibodies, SARS-CoV displays
an altered tropism toward primary human immune cells,
which do not express the conventional virus receptor and
are otherwise refractory to the virus. A number of SARS
vaccine candidates have been tested in experimental
animal models [35,36], many of them based on the viral
Spike glycoprotein previously identified as the most im-
munogenic antigen inducing neutralizing and protect-
ive antibodies [14,15,37,38]. Of note, some vaccines
against animal coronaviruses have been also generated,
but their development has proven difficult due to immune
Figure 5 Susceptibility to ADE is dependent on an intact cytosolic domain. (A) Schematic representation of wild-type and mutated constructs
that were utilized to produce stably transduced ST486 cell lines (see Materials and methods); from top to bottom: human FcγRIIA-His131 (hFcγRIIA-H),
FcγRIIA-Arg131 (hFcγRIIA-R), FcγRIIB1 (hFcγRIIB1) and FcγRIIB2 (hFcγRIIB2). B) Surface expression in stably transduced ST486 cell lines was evaluated by
flow cytometry using a mouse monoclonal anti-FcγRII antibodies (dark grey) or isotype control (light grey), and expressed as mean fluorescence
intensity in Arbitrary Units (AU) as described under Materials and methods. Constructs are identified by Arabic numbers and grouped from top
to bottom as indicated in A. C) Immune complex-binding ability of wild-type, truncated and chimeric FcγR receptors. SARS-CoVpp were incubated
with purified mouse anti-Spike IgG (dark grey) or control IgG (light grey) to form immune complexes, which were then added to the ST486
transfectants (see Materials and methods). After washing and fixation, bound immune complexes were detected by flow cytometry with an
FITC-conjugated goat anti-mouse F(ab’)2, and results shown as in B. Constructs are identified by Arabic numbers and grouped from top to
bottom as indicated in A. D) Susceptibility of ST486 transfectants to ADE of infection by SARS-CoVpp. SARS-CoVpp were incubated with purified
mouse anti-Spike IgG (dark grey) or control IgG (light grey) and then used to infect cells (see Materials and methods). Cells were washed and three days
post infection incubation was stopped by adding luciferase substrate to measure enzymatic activity, which was expressed as Relative Luminescence
Units (RLU). Constructs are identified by Arabic numbers and grouped from top to bottom as indicated in A. Results are shown as the means ± SEM of
three (B and C) or 4–5 independent experiments (D). *P < 0.05; **P < 0.01 by the unpaired Student’s t test.
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Despite the fact that this alternative infection pathway
appears to have a limited impact, it remains of interest
to appreciate the cost of antibody-mediated SARS-CoV
infection on the functionality of the target cells, in
order to have a broad understanding of the tropism and
pathogenesis of the virus and evaluate potential pitfalls
associated with immunization against human corona-
viruses. This aspect is gaining more relevance as the
emergence of the MERS-CoV further indicates that the
availability of vaccines targeting this group of viruses,
which have demonstrated the ability to jump species, is
one of the few options available to prevent the spreadof infections causing severe diseases with high mortality in
humans [42].
Materials and methods
Cell lines and expression vectors
The following cell lines used in the study were obtained
from the American Type Culture Collection (ATCC;
Manassas, VA, USA): HEK293T (human kidney epithelial
cells; CRL-11268), Raji (Burkitt’s lymphoma/B lympho-
blast), ST486 (Burkitt’s lymphoma/B lymphoblast lacking
expression of FcγR; CRL-1647). HEK293T cells were cul-
tured in DMEM supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 0.6 mg/l penicillin and 60 mg/l
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RPMI-1640 supplemented with 10% heat-inactivated FBS,
1% non-essential amino-acids, 4 mM L-glutamine, 1 mM
sodium pyruvate, 0.6 mg/l penicillin, 60 mg/l strepto-
mycin, and 20 μM 2-ß-mercaptoethanol (all from Invitro-
gen Life Technologies, Carlsbad, CA, USA). All cells were
maintained at 37°C in a humidified atmosphere with 5%
CO2 supply.
Culture of human monocyte-derived macrophages
The research protocol was approved by the Institutional
Review Board of the University of Hong Kong/Hospital Au-
thority Hong Kong West Cluster (UW09-375). Blood sam-
ples of healthy donors were obtained from the Hong Kong
Red Cross Blood Transfusion Service. Human blood cells
were isolated from buffy coats and monocyte-derived mac-
rophages were generated in vitro using a modified protocol
as previously described [24,43]. Briefly, mononuclear cells
were isolated by a Ficoll-Paque density gradient (Pharmacia
Biotech, Uppsala, Sweden) to remove erythrocytes, granulo-
cytes, and cell debris. Monocytes were enriched by plastic
adherence, harvested, seeded (106 cells/ml) on tissue cul-
ture plates and allowed to differentiate for 14 days in the
presence of 5% autologous human plasma and 1% fetal calf
serum before use. The purity of macrophages was consist-
ently above 90%, as ascertained by immunofluorescence
staining for human CD68, a lysosomal glycoprotein that is
highly expressed by macrophages and monocytes [44,45].
Production of anti-Spike immune serum
BALB/c mice were immunized with recombinant SARS-
CoV Spike proteins adjuvanted with alum, as previously
described [15,16]. Saline-injected mice served as controls.
Serum was collected at day 55 post-immunization, heat-
inactivated for 30 min at 56°C and stored at −20°C for
subsequent use.
Production and use of lentiviral particles pseudotyped
with SARS-CoV Spike
The protocol to produce SARS-CoV pseudotyped lenti-
viral particles expressing a luciferase reporter gene (SARS-
CoVpp) has been described elsewhere [17]. Following a
purification step on 20% sucrose cushion, the concentrated
viral particles were titrated by ELISA for lentivirus-associated
HIV-1 p24 protein according to the manufacturer’s in-
struction (Cell Biolabs, Inc., San Diego, CA, USA), and
stored at −80°C until use. For ADE assays, heat-inactivated
mouse anti-Spike or control serum was incubated for 1 hr
at 37°C with SARS-CoVpp. This inoculum was deposited
on cells and infection proceeded for 1 hr at 37°C. Following
repeated washing cells were incubated for additional 60–65
hours and then fixed in 4% paraformaldehyde (Sigma-
Aldrich Inc., St. Louis, MO, USA) for immunofluores-
cence microscopy.Infection with replication-competent SARS-CoV
Laboratory procedures involving replication-competent
viruses were performed in biosafety level-3 containment
(State Key Laboratory of Emerging Infectious Diseases,
The University of Hong Kong). The SARS-CoV strain
used (HK39849) is a clinical isolate [46], which was
cultured in fetal rhesus kidney-4 (FRhK-4, ATCC code
CRL-1688) cells. In ADE assays, heat-inactivated mouse
anti-Spike or control serum was incubated for 1 h at 37°C
with SARS-CoV and human monocyte-derived macro-
phages were infected at an MOI of 1 for 60 min at 37°C.
After repeated washings, cells were cultured with fresh
medium (time 0) supplemented with 2% FBS for the indi-
cated time points (hours) post infection (p.i.) and eventu-
ally either fixed in 4% paraformaldehyde (Sigma-Aldrich
Inc.) for immunofluorescence microscopy, or resuspended
in lysis buffer (RLT buffer, RNeasy RNA Mini kit; QIA-
GEN, Germantown, MD, USA) for real-time quantitative
RT-PCR. Samples of cell culture supernatants harvested
at different h.p.i. were also mixed with RLT buffer and
processed as above for RT-PCR.
Immunofluorescence microscopy
Infectivity of replication-competent SARS-CoV was deter-
mined by indirect immunofluorescence with a mouse
monoclonal antibody directed against SARS-CoV nucleo-
capsid protein (clone 4D11; a gift from Dr. Kwok-Hung
Chan, Department of Clinical Microbiology, Queen Mary
Hospital, Hong Kong), at a dilution of 1:200. Staining
was revealed with a tetramethylrhodamine-5-(and-6)-
isothiocyanate (TRITC) conjugated goat anti-mouse
antibody (Invitrogen Life Technologies) on an AxioObser-
ver Z1 microscope (Carl Zeiss, Inc., Thornwood, New
York, USA). Pictures taken from 5 randomly chosen fields
at a magnification of 400X were acquired with an Axiocam
MRm camera and analyzed with Metamorph software
(Molecular Devices, Sunnyvale, CA, USA). Infectivity was
determined as the percentage of cells expressing viral anti-
gen. Similar staining procedures were employed for asses-
sing infection by SARS-CoVpp, except for the use of
direct immunofluorescence with a fluorescein isothiocyan-
ate (FITC) conjugated goat monoclonal antibody specific
for firefly luciferase (Rockland, Gilbertsville, PA, USA) at a
dilution of 1:100.
Real-time quantitative RT-PCR for viral gene expression
RNA was extracted with the RNeasy RNA Mini kit
(QIAGEN), according to the manufacturer’s recommen-
dations; concentration and purity of RNA were measured
by standard optical methods. Reverse transcription was
performed on total RNAs with Superscript III reverse
transcriptase as specified by the manufacturer (Invitrogen
Life Technologies). For quantification of SARS-CoV gene
copies, cDNA was generated in separate reactions in
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the nucleocapsid and ORF1b genes (Table 1) that ampli-
fied negative and positive strand viral RNAs, respectively.
This assay allows distinguishing between signals generated
by entry of input virus from downstream events reflecting
an active replication process [47]. Specific primers (Table 1)
and TaqMan Minor Groove Binder probes used for detec-
tion of SARS-CoV nucleocapsid gene have been previously
described [48]. However, it should be noted that the primer
set used for the nucleocapsid gene could also detect the
negative strand of the viral genomic RNA and could not
distinguish it from sub-genomic material. The qPCR assay
was carried out in a final volume of 20 μl and the fluores-
cence signal was detected with a LightCycler 480-II (Roche
Applied Science, Mannheim, Germany) programmed as
follows: 95°C for 10 min, followed by 45 cycles of 95°C for
10 sec, 60°C for 30 sec, and 72°C for 1 sec. Results were
expressed as the number of target copies per 108 copies of
the 18S rRNA gene, which was used to normalize results.
To ensure the consistency of qPCR measurements over
the time period of the study, the same batches of primers
and probes were employed. The qPCR results were consid-
ered valid when the efficiency of the standard curve was
between 1.9 to 2.1 and the R2 value was greater than 0.99.
Purification of IgGs from mouse serum
IgGs was purified from immunized and control mice using
protein G-sepharose (GE Healthcare, Little Chalfont, United
Kingdom) according to the manufacturer’s recommenda-
tions. The purity of the IgG fraction was checked by silver
staining following gel electrophoresis and the concentra-
tion of anti-Spike IgG determined by ELISA.
Construction of lentiviral vectors for wildtype,
endodomain-truncated and chimeric forms of FcγRII
(hCD32)
The strategy to produce plasmids for wild-type human
IgG receptors (FcγRs) consisted in replacing the enhanced
green fluorescent protein (eGFP) gene from the bicistronicTable 1 Sequences of primers and probes used in real-time q
Gene Sequences
18S rRNA (F) 5′-CggAggTTCgAAgACgATCA
(R) 5′-ggCgggTCATgggAATAAC
(P) 5′(HEX) ATACCgTCgTAgTTCCgACCA (BHQ)
Nucleocapsid (F) 5′-ACCAgAATggAggACgCAATg
(R) 5′-gCTgTgAACCAAgACgCAgTATTAT
(P) 5′(FAM) ACCCCAAggTTTACCC (NFQ)
ORF1b (F) 5′-CAgAACgCTgTAgCTTCAAAAATCT
(R) 5′-TCAgAACCCTgTgATgAATCAACAg
(P) 5′(FAM) TCTgCGTAggCAATCC (NFQ)
F: forward primer; R: reverse primer; P: TaqMan probes; 18S rRNA: 18S ribosomal RNvector pCHMWS-eGFP_IRES_Hygromycin (a kind gift
from Drs. Rik Gijsbers and Zeger Debyser, Katholieke Uni-
versiteit Leuven, Belgium) with the coding sequences for
FcγRIIA (hCD32a) isoforms (FcγRIIA.R131 and FgRIIA.
H131 GenBank accession No. NM_021642) and FcγRIIB1
(hCD32b; GenBank accession No. AF543826) flanked by
BglII and SalI sites, as described elsewhere [16]. The syn-
thetic sequences (GeneArt, Regensburg, Germany) were
inserted into the original transfer plasmid to yield wild-
type constructs. pCHMWS-FcγRIIB2_IRES_Hygromycin
was constructed by swapping the intracellular domain of
FcγRIIB2, obtained from RT-PCR amplification of the desired
sequence from polyclonal Raji cDNA, with the correspond-
ing region of the pCHMWS-FcγRIIB1_IRES_Hygromycin
construct. Wild-type constructs were subsequently used
to generate truncated and chimeric forms of FcγRIIs by
standard techniques (see Figure 5A for a schematic
representation of the mutants tested). All plasmids
were sequenced by the Centre for Genomic Sciences of
the University of Hong Kong.
Generation of stable ST486 cell lines expressing wild-type
and mutated FcγRs using lentiviral particle-based gene
transduction
Cell lines were generated by transduction of monoclonal
ST486 cells with vesicular stomatitis virus (VSV) G pseu-
dotyped lentiviral particles bearing the specified transgene
as previously described [16]. At 2 days post-infection, cell
surface expression of the FcγRs was monitored by flow cy-
tometry and cells were subsequently cultured in selective
medium containing 250 μg/ml hygromycin (Invitrogen Life
Technologies) when appropriate. Finally, several monoclo-
nal cell lines for each construct were isolated and expres-
sion of the transgene was confirmed by flow cytometry.
Evaluation of FcγR expression on ST486 transfected cell
lines by flow cytometry
Expression of FcγRIIs was evaluated by flow cytometry
as described in [16]. The following mouse MAbs werePCR assay and cDNA synthesis
Amplification product (bp) GeneBank accession number
90 NR_003286
85 AY278491
68 AY278491
A.
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anti-hCD64 (all from BD PharMingen, Frankin Lakes,
NJ, USA); MOPC-21 (IgG1, κ) or MPC-11 (IgG2b, κ)
isotype controls (both from BioLegend, San Diego, CA,
USA). Cells were washed and primary antibody binding
was revealed by staining on ice for 30 min with FITC-
conjugated goat anti-mouse antibodies (Jackson Immu-
noResearch, West Grove, PA, USA). Data were collected
from at least 10,000 singlet living cells on a LSRII flow cyt-
ometer (BD Biosciences, San Jose, CA, USA) and analyzed
using FlowJo software (TreeStar, Ashland, OR, USA).
Binding of immune complexes to FcγRII
SARS-CoVpp-IgG immune complexes were obtained by
incubating SARS-CoVpp with 30 μg/ml of either puri-
fied mouse anti-Spike or control IgG at 37°C for 1 hr.
The mixture was then quickly chilled on ice for 10 min
and added (100 μl/well) to ST486 cells (3×105 cells/well),
which had been previously stained with 0.1% fixable viabil-
ity dye eFluor 660 (eBioscience, San Diego, CA, USA). Fol-
lowing a 1 hr incubation on ice, cells were washed twice
with cold PBS, fixed with 1% paraformaldehyde for 20 min
on ice and immune complex binding was revealed by
staining with 5 μg/ml FITC-conjugated goat anti-mouse
F(ab’)2 (Jackson ImmunoResearch) at 4°C for 30 min.
Data were collected and analysed as described above.
Statistical analysis
Results are shown as means ± SEM of the indicated
number of observations. Statistical difference between
groups was determined by the unpaired Students’s t-test
with a 0.05 significance level.
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